FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Protagonist Therapeutics, Inc. Announces Removal of FDA Clinical Hold on the Rusfertide Clinical Development Program”
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) surged over 86% in premarket trading after the U.S. FDA removed the full clinical hold on the Company’s rusfertide clinical studies.
The Company has provided the FDA with all requested information as the basis for a Complete Response and subsequent removal of the clinical hold and is now looking forward to its Phase 3 registrational trial, planned to commence in the first quarter of 2022.
Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based investigational new chemical entities in different stages of development, all derived from the Company’s proprietary technology platform. Protagonist’s pipeline includes rusfertide (PTG-300), an investigational, injectable hepcidin mimetic in a Phase 2 proof-of-concept clinical trial for polycythemia vera (PV), a Phase 2 study in PV subjects with high hematocrit levels, and a Phase 2 study for hereditary hemochromatosis.
For more information, please visit: Protagonist Therapeutics, Inc.
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.
The post “The Buzz” Show: Protagonist Therapeutics (NASDAQ: PTGX) FDA Lift on Rusfertide Clinical Hold first appeared on Financial Buzz .
For further details see:
“The Buzz” Show: Protagonist Therapeutics (NASDAQ: PTGX) FDA Lift on Rusfertide Clinical Hold